What’s going on here? The Bank of Canada's next rate decision hangs in the balance, with mixed signals from rising unemployment and strong Q1 GDP growth indicating conflicting economic health. ING ...

Three-year low: With the crucial spring homebuying season ahead, real estate agents finally have something fresh to sell: the lowest mortgage rates in three years. The big question is whether that ...

Neel T. Kashkari, president of the Federal Reserve Bank of Minneapolis, defended Jerome H. Powell, the Fed chair, in an interview. He also said interest rates should be held steady this month. By ...

Shares in mortgage lenders jumped after President Donald Trump instructed "representatives" to purchase mortgage bonds. Trump said he aimed to bring down rates and monthly payments. Shares in mortgage ...

The Student Experience Survey, which allows students to provide anonymous feedback to instructors on their learning experience, has seen a 23.3% increase fall 2025 from Spring 2025 responses. The ...

IREN Limited transitions from Bitcoin mining to AI infrastructure, leveraging a $9.7B Microsoft contract to drive future growth. IREN’s low-cost Bitcoin mining provides steady cash flow, but AI data ...

Zugo-cel, targeting CD19, is in an ongoing Phase 1 basket trial in autoimmune rheumatologic diseases. Preliminary clinical data from the Phase 1 study have been encouraging, and zugo-cel has been well ...

David M. Hart is a senior fellow for climate and energy at the Council on Foreign Relations. While China drives an electric revolution in the global auto industry, the United States has retreated, ...

The Trump administration looked to recast elements of a dour jobs report Tuesday as a sign of strength. By Tony Romm Reporting from Washington The White House on Tuesday sought to recast a dour ...

ORLANDO -- For triple-class exposed relapsed or refractory multiple myeloma with extramedullary disease (EMD), a combination of talquetamab (Talvey) and teclistamab (Tecvayli) achieved high response ...

The treatment regimen achieved a 100% overall response rate, with 95% of patients reaching complete response after brexucabtagene autoleucel infusion. Safety concerns included cytokine release ...